ScinoPharm Taiwan, Ltd.
Research ScinoPharm Taiwan, Ltd. (1789.TW) on Bullrun: market cap TWD 15.58B, P/E 394.0, dividend yield 1.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1789.TW
- ExchangeTW
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyTWD
- Market capTWD 15.58B
- P/E394.0
- Dividend yield1.5%
- Financial periodQ2 2026
- RevenueTWD 678.51M
- Net income-TWD 35.53M
- Free cash flowTWD 219.43M
- Gross margin19.8%
Valuation Snapshot
latest market cap is TWD 15.58B; P/E is 394.0; dividend yield is 1.5%.
Peer valuation comparison
Latest P/E is 394x versus a Healthcare sector median of 21.8x (1707.7% above).
Latest dividend yield is 1.45% versus a Healthcare sector median of 2.4% (39.6% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 15.58B | 394.0 | 1.5% | 0.29 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.29 TWD, yield 1.5%.
About ScinoPharm Taiwan, Ltd.
ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract manufacturing, and small molecules and peptide contract development and manufacturing organization services.
ETFs that hold ScinoPharm Taiwan, Ltd.
US-listed ETFs
ScinoPharm Taiwan, Ltd. is held by 14 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Avantis Emerging Markets Equity ETF (AVEM) | <0.01% | 0.33% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | <0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ScinoPharm Taiwan, Ltd.'s market cap?
ScinoPharm Taiwan, Ltd.'s market capitalization is TWD 15.58B.
What is ScinoPharm Taiwan, Ltd.'s P/E ratio?
ScinoPharm Taiwan, Ltd.'s price-to-earnings (P/E) ratio is 394.0.
Does ScinoPharm Taiwan, Ltd. pay a dividend?
ScinoPharm Taiwan, Ltd. has a dividend yield of 1.5%.
What does ScinoPharm Taiwan, Ltd. do?
ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract manufacturing, and small molecules and peptide contract development and manufacturing organization services. The company was incorporated in 1997 and is headquartered in Tainan City, Taiwan.